Evidence map›Paper›PMID 31932259›Full record

SynthesisJournal of geriatric oncology2020

The underreporting of phase III chemo-therapeutic clinical trial data of older patients with cancer: A systematic review.

Karlynn BrintzenhofeSzoc, Jessica L Krok-Schoen, Beverly Canin, Ira Parker, Amy R MacKenzie, Thuy Koll, Ritika Vankina, Christine D Hsu, Brian Jang, Kathy Pan and 3 more

Open access · greenAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of geriatric oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 1 country.

Karlynn BrintzenhofeSzocCollege of Allied Health Sciences, School of Social Work, University of Cincinnati, USA. Electronic address: karlynn.brintzenhofeszoc@uc.edu.
Jessica L Krok-SchoenSchool of Health and Rehabilitation Sciences, The Ohio State University, USA.
Beverly CaninCancer and Aging Research Group, USA.
Ira ParkerGeriatric Oncology Solutions, USA.
Amy R MacKenzieThomas Jefferson University, USA.
Thuy KollDepartment of Internal Medicine, University of Nebraska Medical Center, USA.
Ritika VankinaHarbor-UCLA Medical Center, USA.
Christine D HsuUniversity of North Carolina at Chapel Hill, USA.
Brian JangTulane University School of Medicine, USA.
Kathy PanHarbor-UCLA Medical Center, USA.
Jennifer L LundUniversity of North Carolina at Chapel Hill, USA.
Edith StarbuckUniversity of Cincinnati Libraries, University of Cincinnati, USA.
Armin ShahrokniMemorial Sloan Kettering Cancer Center, USA.
Harbor–UCLA Medical Center · USUniversity of North Carolina at Chapel Hill · USMemorial Sloan Kettering Cancer Center · USThe Ohio State University · USThomas Jefferson University · USTulane University · USUniversity of Cincinnati · USUniversity of Cincinnati Medical Center · USUniversity of Nebraska Medical Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Tracking and Evaluation CoreU54GM115458 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI PHILIBERT, INGRID · 2016 to 2025
$42.8M
An Expanded Framework to Measure Cognitive Function in Older Adults Undergoing Hematopoietic Cell TransplantationR03AG060095 · NIA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI KOLL, THUY · 2019 to 2020
$229k
NCI NIH HHS P30 CA008748NIA NIH HHS R03 AG060095NIGMS NIH HHS U54 GM115458
6 · The paper itself

Abstract

purposeInspired by the American Society of Clinical Oncology's recommendations to strengthen the evidence base for older adults with cancer, the purpose of this systematic review is to identify the reporting of treatment efficacy and adverse events specific to older adults with cancer in Phase III chemo-therapeutic clinical trials. This review also investigates the frequency with which these data points were reported in the literature to identify gaps in reporting and opportunities to expand the knowledge base on clinical outcomes for older adults with cancer.

methodsChemo-therapeutic clinical trial data published from July 1, 2016 to June 30, 2017 was reviewed. Manuscripts (n = 929) were identified based on keyword searches of EMBASE and PubMed. After removal of duplicates (n = 116) and articles that did not meet this study's inclusion criteria (n = 654), 159 articles were identified for review.

resultsReviewed papers were published in 36 different scientific journals and included twenty-five different cancer types. Of the 159 articles, 117 (73.6%) reported age-specific medians and 75 (47.2%) included stratifications of data by age. Treatment efficacy was reported in 96.2% of the articles with 39.9% reporting effectiveness of treatment by age. Reporting of adverse events was included in 84.9% of the articles with only 8.9% reporting these events stratified by age.

conclusionResults suggest inadequate reporting of treatment efficacy and adverse events as well as basic descriptive statistics about the age distribution of study subjects. Conscious efforts are needed to address these deficiencies at every level of planning and conducting clinical trials as wells as reporting outcomes stratified by age. Ultimately, standardized reporting could lead to improved treatment decisions and outcomes for older adults with cancer.

Indexed as

NeoplasmsAgedClinical Trials, Phase III as TopicFemaleHumansMaleTreatment OutcomeUnited StatesGeriatric oncologyOlder adultsPhase III clinical trialsSystematic review

Identifiers

PMID31932259
PMCPMC7412117
OpenAlexW2998772713

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.